CJC 1295 NO DAC 2mg

CJC 1295 NO DAC 2mg
Details:
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablets
(3)Injection
(4)Capsules
(5)Cream
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: KP-3-3/005
CJC 1295 NO DAC CAS 446036-97-1
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
Send Inquiry
Description
Send Inquiry

CJC 1295 NO DAC 2mg, It is an artificially synthesized growth hormone releasing hormone (GHRH) analog with a molecular formula of C152H252N44O42 and a molecular weight of 3367.89688 g/mol. White to off white powder, slightly soluble in water, ethanol, and methanol, needs to be stored in an inert gas environment at -20 ℃ to prevent degradation. Its core structure retains the biologically active region of natural GHRH (amino acids 1-29), but without the addition of drug affinity complexes (DAC) modification, resulting in a short half-life (approximately 30 minutes to several hours) and requiring frequent administration to maintain effective blood drug concentration.

 
Our Product Form
 
cjc 1295 injection | Shaanxi BLOOM Tech Co., Ltd
cjc 1295 no dac injection | Shaanxi BLOOM Tech Co., Ltd
cjc 1295 tablets | Shaanxi BLOOM Tech Co., Ltd
cjc 1295 spray | Shaanxi BLOOM Tech Co., Ltd
CJC 1295 cream | Shaanxi BLOOM Tech Co., Ltd
cjc 1295 powder | Shaanxi BLOOM Tech Co., Ltd

CJC 1295 price list | Shaanxi BLOOM Tech Co., Ltd

CJC 1295 price list | Shaanxi BLOOM Tech Co., Ltd

CJC-1295 COA

 

cjc 1295 COA | Shaanxi BLOOM Tech Co., Ltd

 

cjc 1295 dac Information | Shaanxi BLOOM Tech Co., Ltd

 

product-338-68

The core difference between CJC 1295 NO DAC 2mg and CJC-1295 (usually referring to the version containing DAC) lies in the pharmacokinetic properties caused by differences in molecular structure modifications. The former demonstrates significant advantages in safety, physiological adaptability, and long-term feasibility by simulating the pulsatile secretion mode of natural growth hormone releasing hormone (GHRH).

Differences in molecular structure and modification: The "double-edged sword" effect of DAC
 

The essential difference between CJC-1295 No DAC and the version containing DAC is whether it carries a Drug Affinity Complex (DAC). DAC is a modification group covalently bound by lysine and maleimide propionic acid (MPA), with a molecular weight of 500-600 Da. Through non covalent binding with plasma albumin, it significantly prolongs the retention time of drugs in the bloodstream.

Including DAC version:

The DAC group can bind with albumin to form a complex with a molecular weight of approximately 40 kDa, extending the half-life of the drug to 8 days. Although this modification reduces the frequency of administration (1-2 times per week), it leads to sustained drug release in the body, disrupting the natural pulsatile secretion pattern of GHRH (pulses every 3-4 hours in the circadian rhythm).

cjc 1295 dac structure | Shaanxi BLOOM Tech Co., Ltd

 

cjc 1295 no dac structure | Shaanxi BLOOM Tech Co., Ltd

No DAC version:
Without the addition of DAC groups, the molecular weight is only 3.4 kDa, with a half-life of approximately 30 minutes to several hours. Its metabolic characteristics are closer to natural GHRH, and by simulating physiological pulse secretion, it avoids the risk of receptor desensitization. For example, after a single injection of 2 μ g/kg No DAC in healthy subjects, plasma GH levels increased 2-10 times within 2 hours and returned to baseline within 6 hours, consistent with the duration of physiological pulses.

Metabolic Dynamics Advantage: Physiological Adaptability of Pulse Release
 

The metabolic characteristics of CJC 1295 NO DAC 2mg make it superior to the DAC containing version in the following aspects:
Receptor activation mode:
Natural GHRH activates the GHRH receptor (GHRH-R) on the anterior pituitary cell membrane through pulsed release, triggering the cAMP/PKA signaling pathway and promoting GH gene transcription. The DAC containing version may cause sustained activation of GHRH-R due to sustained release, which may lead to receptor phosphorylation and endocytosis, reducing receptor sensitivity. Animal experiments have shown that long-term use of rats containing the DAC version reduces pituitary GH reserve by 30%, while this phenomenon was not observed in the No DAC version.

cjc 1295 dac release | Shaanxi BLOOM Tech Co., Ltd

 

cjc 1295 no dac axis | Shaanxi BLOOM Tech Co., Ltd

GH/IGF-1 axis regulation:
No DAC activates the hepatic GH receptor (GHR) and promotes IGF-1 synthesis through pulsed release of GH. The half-life of IGF-1 is about 20 hours, and its level fluctuates synchronously with GH pulses. The version containing DAC may lead to excessive elevation of IGF-1 levels due to sustained GH release, increasing the risk of metabolic complications such as insulin resistance and joint pain. Clinical data shows that the IGF-1 levels of users with No DAC version increase by 1.5-3 times within 9-11 days, while users with DAC version can experience an increase of 3-5 times in IGF-1 levels, with greater fluctuations.

 

Drug clearance pathway:
No DAC is mainly cleared through renal filtration (molecular weight<50 kDa) and protease degradation, with no risk of liver toxicity accumulation. The version containing DAC may be metabolized through the endocytic pathway of liver cells due to its binding with albumin, increasing the burden on the liver. When using the No DAC version in patients with renal insufficiency (creatinine clearance rate<30 mL/min), the dose should be halved; The DAC containing version, due to its metabolic dependence on albumin, requires dose adjustment based on liver function.

cjc 1295 no dac clearance | Shaanxi BLOOM Tech Co., Ltd

Physiological effect optimization: multi tissue repair and metabolic regulation

 

cjc 1295 no dac effcet | Shaanxi BLOOM Tech Co., Ltd

CJC-1295 No DAC achieves physiological effect optimization by precisely regulating the GH/IGF-1 axis at the following levels:
Muscle growth and repair:
GH promotes muscle fiber hypertrophy by activating satellite cell proliferation and the IGF-1 mediated mTOR pathway. The No DAC version of pulsed GH release can prevent muscle cell apoptosis caused by sustained high concentrations of GH (by activating the JNK pathway). Animal experiments showed that users of the No DAC version had a 40% increase in muscle contusion repair area compared to the control group within 48 hours, while users of the DAC version only had a 25% increase in repair area.

 

Fat metabolism:
GH promotes fat oxidation by upregulating lipase activity and inhibiting adipocyte differentiation. The No DAC version of pulsed GH release can avoid insulin resistance in adipocytes caused by sustained high concentrations of GH (by inhibiting GLUT4 transport). After using the No DAC version in obese patients, visceral fat area decreased by 12% and fasting blood glucose decreased by 0.8 mmol/L; And users with the DAC version experienced an 8% reduction in visceral fat and a 0.5 mmol/L decrease in blood sugar.

cjc 1295 no dac GH | Shaanxi BLOOM Tech Co., Ltd

 

cjc 1295 no dac bone | Shaanxi BLOOM Tech Co., Ltd

Bone metabolism:
GH stimulates osteoblast proliferation, while IGF-1 promotes bone matrix synthesis. The No DAC version of pulsed GH release can avoid the increased bone resorption caused by sustained high concentrations of GH (by inhibiting the RANKL/OPG ratio). After using the No DAC version in the osteoporosis model mice, the thickness of bone trabeculae increased by 25% and the fracture healing time was shortened by 30%; Users with the DAC version experience an 18% increase in trabecular thickness and a 20% reduction in healing time.

CJC-1295 No DAC significantly outperforms the DAC containing version in terms of metabolic kinetics, physiological effects, and safety by simulating the pulsatile secretion mode of natural GHRH. Its pulsed GH release can avoid receptor desensitization and metabolic disorders, achieving more precise regulation of muscle growth, fat metabolism, and bone repair.

Applications

CJC 1295 NO DAC 2mg is an artificially synthesized growth hormone releasing hormone (GHRH) analog that simulates the physiological function of natural GHRH, activates anterior pituitary cells to release growth hormone (GH), and regulates metabolism, promotes tissue repair and growth through the GH/IGF-1 axis.

Molecular Structure Fundamentals: Accurate Simulation and Optimization of GHRH
 

Molecular design is based on the active core region (1-29 amino acids) of natural GHRH (1-44 peptide), and functional enhancement is achieved through structural optimization as follows:

Amino acid sequence optimization: Retain key residues in GHRH (1-29) that bind to receptors (such as Tyr ¹, Asp ³, Phe ⁶, Arg ¹⁹, Lys ² ⁰), while replacing some amino acids (such as Ala ² replacing D-Ala and Leu ² ⁸ replacing Ile) to enhance stability.

cjc 1295 no dac GHRH | Shaanxi BLOOM Tech Co., Ltd

 

cjc 1295 no dac bund | Shaanxi BLOOM Tech Co., Ltd

C-terminal modification: Add an amide bond (- CONH ₂) at the C-terminal to protect the peptide chain from degradation by carboxypeptidase, extending the half-life to 30 minutes to several hours (the natural GHRH half-life is only 2-5 minutes).
No DAC modification: Unlike those containing DAC, the No DAC version does not add drug affinity complexes (DAC) to avoid half-life extension caused by binding to plasma albumin (the DAC version has a half-life of up to 8 days), thus retaining a more physiological pulsatile GH release mode.

Receptor activation mechanism: specific binding of GHRH receptor
 

CJC-1295 No DAC activates the GHRH receptor (GHRH-R) on the anterior pituitary cell membrane through the following steps:

Receptor recognition: The N-terminus (Tyr ¹ - Asp ³) of No DAC binds to the extracellular domain (ECD) of GHRH-R, forming hydrogen bonds and hydrophobic interactions; The C-terminal (Arg ¹⁹ - Lys ² ⁰) binds to the pocket region of the receptor transmembrane domain (TMD), stabilizing the receptor conformation.
Conformal change: After receptor binding, TMD rotates, activating intracellular G protein (Gs α) and leading to activation of adenylate cyclase (AC).

cjc 1295 no dac cell | Shaanxi BLOOM Tech Co., Ltd

 

cjc 1295 no dac catalyzes | Shaanxi BLOOM Tech Co., Ltd

Second messenger generation: AC catalyzes the conversion of ATP into cyclic adenosine monophosphate (cAMP), which acts as a second messenger to activate protein kinase A (PKA) and subsequently phosphorylate downstream target proteins (such as CREB).
Key evidence:

In vitro experiments have shown that No DAC can significantly stimulate primary rat pituitary cells to release GH at a concentration of 10 ⁻⁹ M, with an effect comparable to natural GHRH.
Molecular docking simulations have confirmed that the binding free energy of No DAC to GHRH-R (-52.3 kcal/mol) is lower than that of natural GHRH (-48.7 kcal/mol), indicating a stronger binding affinity.

Signal pathway regulation: cascaded amplification of GH/IGF-1 axis
 

CJC 1295 NO DAC 2mg activates GHRH-R, triggering the following signaling pathways to ultimately achieve GH synthesis and secretion:

GH gene transcriptional activation: PKA phosphorylates CREB, promoting the binding of cAMP response elements (CRE) in the GH gene promoter region and enhancing GH mRNA transcription.
GH secretion regulation:
Acute effect: cAMP promotes the fusion of GH secretory granules with the cell membrane through the Epac (exchange protein directly activates cAMP) pathway, achieving rapid release (within minutes).

Chronic effects: PKA phosphorylates the lipid phosphatase PTEN, inhibits the PI3K/Akt pathway, and reduces negative feedback inhibition of GH secretion.

cjc 1295 no dac pathway | Shaanxi BLOOM Tech Co., Ltd

 

cjc 1295 no dac GH | Shaanxi BLOOM Tech Co., Ltd

IGF-1 synthesis: GH activates the JAK2/STAT5 pathway through the GH receptor (GHR) on the liver cell membrane, promoting the synthesis and release of insulin-like growth factor-1 (IGF-1). IGF-1 further enhances the growth of muscles, bones, and other tissues through its autocrine/paracrine effects.

Clinical data support:

After a single injection of No DAC (2 μ g/kg) in healthy subjects, plasma GH levels increased by 2-10 times within 2 hours and lasted for 6 days; IGF-1 levels increase by 1.5-3 times within 3 days and persist for 9-11 days.
Long term use (12 weeks) can significantly increase lean body mass (+2.3 kg), reduce fat mass (-1.8 kg), and increase bone density (+1.5%).

 

Hot Tags: cjc 1295 no dac 2mg, China cjc 1295 no dac 2mg manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, biotinoyl tripeptide 1 uses, glp1 shot, etelcalcetide structure

Send Inquiry